Registry update — unassessed
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
OTHERRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 21, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- Open-label design without control group cannot establish efficacy or isolate drug effects from placebo response. No outcome data were reported, so no claims about the intervention's effects can be evaluated. The study design and population do not determine whether senolytics specifically address aging in psychiatric conditions or only depression/schizophrenia symptoms.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Other
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- —
- Effect size
- —
- Significance
- Not reported
- Journal
- Washington University School of Medicine
- Published
- Apr 21, 2026
Sources
Primary source
- Washington University School of Medicine ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.